Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02248636 · ClinicalTrials.gov registry record · Phase 2
Cholinesterase Inhibitor Discontinuation
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT02248636: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT02248636 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 72 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02248636, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study tries to determine if stopping certain medications that are used to treat dementia will cause worsening from the patient and family perspective. All of the participants will take pills that look identical, and that may contain active drug or an inactive pill (a placebo). Half of the group will receive the same treatment they were taking before the study -- this is called the "sham discontinuation" arm. The other half will receive a reduced dose of their medication, and then an inactive pill (placebo) -- this is called the "real discontinuation" arm. Participants will be able to return to their previous dose of medication at any time during the study. The percentage of people who return will be measured and compared. Other medical events and factors such as behaviors, thinking, and caregiver distress, will be measured and compared between the groups.
Interventions
- DRUG Cholinesterase inhibitor
- DRUG Sham discontinuation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2015-01-22 |
| Est. Completion | 2019-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02248636
The ClinicalTrials.gov registry entry for NCT02248636 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cholinesterase inhibitor is the first listed.
NCT02248636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02248636 about?
NCT02248636 is a clinical study titled "Cholinesterase Inhibitor Discontinuation". This study tries to determine if stopping certain medications that are used to treat dementia will cause worsening from the patient and family perspective. All of the participants will take pills that look identical, and that may contain active drug or an inactive pill (a placebo). Half of the grou...
What is the current status of trial NCT02248636?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2015-01-22. Estimated completion is 2019-10-01.
What interventions are being tested in trial NCT02248636?
The interventions under investigation include: Cholinesterase inhibitor (DRUG), Sham discontinuation (DRUG).
Who is sponsoring clinical trial NCT02248636?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.